Infectious Disease



Infectious Disease




Med Lett Drugs Ther 2001;43:69; 2002;44:9



10.1 Fournier Gangrene

Cause: Polymicrobial infection of scrotum from skin, urethral or perianal nidus.

Epidem: Uncommon; mortality rate from 20-42% in adults; increased risk in older age and those with chronic alcoholism (Eur Urol 1998;34:411).

Pathophys: Most commonly seen in those with diabetes mellitus or other immunocompromised states, the scrotal area is at risk for secondary or rapidly progressing infections.

Sx: Scrotal pain, rectal pain, dysuria.

Si: Hard and erythematous scrotum, diffuse tenderness, fever.

Crs: May be protracted and lead to death; less ominous course in children (Urology 1990;35:439).

Cmplc: May progress to abscess formation or necrotizing fasciitis; acute renal failure; adult respiratory distress syndrome (Brit J Urol 1989;64:310).

Diff Dx: May arise from intra-abdominal processes (Urology 1994;44:779).

Lab: Glucoscan with serum glucose if elevated, HgbA1C if undiagnosed diabetic, UA, metabolic profile—metabolic abnormalities correspond with severity of disease (J Urol 1995;154:89).



Emergency Management:



  • IVF and parenteral antiemetics and/or pain medications, if needed.


  • Iv ampicillin/sulbactam, second generation cephalosporin or antibiotic combination to give coverage for Gram-pos, Gram-neg, and anaerobes.


  • Treat underlying metabolic disorders, such as hyperglycemia.


  • Topical unprocessed honey (Surgery 1993;113:200).


  • Hyperbaric oxygen is controversial (J Urol 1984;132:918).


  • Urologic consult.


10.2 HIV

N.B. This is a dynamic field; identify local experts and resources. Adv IM 2000;45:1; AIDS Read 2000;10:133 and the entire issue of


Cause: Human immunodeficiency virus (HIV) type 1; rarely in U.S., but commonly found in Africa is HIV type 2; a retrovirus.

Epidem: Spread via sexual intercourse; dirty shared needles; blood products, eg, screened blood transfusion 1996 risk = 1:500,000, factor VIII concentrates, and probably breast milk; rarely by casual or nonsexual familial contact, and percutaneous inoculation in health care workers—0.3% incident that increases with volume and HIV titer. Transmission enhanced by the presence of chancroid or other genital ulcers.

Prevalence increased in men who have sex with men, drug users, hemophiliacs, female partners of infected males.

90% of persons transfused with HIV-pos blood convert to pos themselves; 30% of babies from HIV-pos mothers who are untreated are pos at 6 mon of age.


Pathophys: AIDS defined by HIV infection and T4 count < 200 (Semin Thorac Cardiovasc Surg 2000;12:130).

Increased suppressor T8 and decreased helper T4 cells (CD4); deficient production of interferon γ. Conversion rate of HIV pos to AIDS is approximately 2% per yr in hemophiliacs, but is age-dependent so that 7% of HIV-pos young hemophiliacs have AIDS after 8 yr, but 50% of those who are age 35-70 yr will have AIDS after 8 yr, and this is a similar pattern in homosexuals.

Billions of virons produced daily from infection with high viral RNA mutation rate that allows rapid selection of resistant organism in the face of treatment. Also sequestration of virus in lymphoid tissue (J Infect Dis 2000;181:354). Oxidative stress of illness appears to be reversed with effective therapy (J Acquir Immune Defic Syndr 2000;23:321).

Sx: Primary HIV infection: mono-like syndrome 5-30 d after exposure, lasting approx. 2 wk; fever (95%), sore throat (70%), weight loss (70%), myalgias (60%), headache (60%), cervical adenopathy (50%).



  • AIDS: Diarrhea (60%), malaise, weight loss, fever adenopathy, dyspnea.

Si: Early: lymphadenopathy; oral monilia/thrush (exudative, chelosis or erythematous diffuse rash types) precedes overt disease often; dermatoses including warts and shingles; chronic fatigue syndrome.



  • Later: wasting syndromes; chronic diarrhea, Kaposi sarcoma, hairy leukoplakia corrugations on sides of tongue due to reactivation of EBV.

Crs: Variable RNA viral loads in first 4 mon, but worse course predicted by levels at 5-12 mon from infection and by severity of primary infection symptoms.

Of HIV infection: evolution to AIDS 10-yr postseroconversion varies from 0-72% inversely with RNA copies (viral load) at 12-18 mon after seroconversion.


Of AIDS: 1997 mortality figures markedly improving with aggressive multi-drug treatment based on viral loads, eg, from 29 to 9:100 person yr in pts with CD4 counts < 100; older data were 50% 1-yr, 15% 5-yr survival, 5% 10+-yr survival because of some viral attenuated pathogenicity; in pts with AIDS on AZT, 50% 1-yr survival after CD4 count < 50/mm3; increased time to clinical AIDS and opportunistic infections (AIDS 2000;14:561). Prognosis (survival) worse with increasing age, but not associated with gender, iv drug use, race, or socioeconomic status.




  • Infections with common bacterial pathogens, as well as opportunistic organism, especially when CD4 count < 50 include the following [less since highly active anti-retroviral therapy (J Acquir Immune Defic Syndr 2000;23:145)]:

    Pneumocystis or other pneumonias (J Infect Dis 2000;181:158)

    TB, and as a marker for HIV risk based on CD4 and CD8 ratio (AIDS Patient Care STDS 2000;14:79).

    Atypical mycobacterium, especially M. avium M. intracellulare, rarely M. haemophilum or M. fortuitum (Am J Med Sci 1998;315:50).

    Herpes infections including tongue fissures: CMV; Candida; Aspergillosis; Strongyloides.


    Nocardia

    Mucor

    Cryptococcus, especially meningitis

    Toxoplasma

    Legionella

    Chlamydia, Gonorrhea perhaps as marker for HIV risk (AIDS 2000;14:189), and other STDs (Sex Transm Dis 2000;27:259)

    Monilia and torulopsis

    Cryptosporidiosis (Nejm 2002;346:1723)


    Isospora belli

    Listeria

    Cat scratch Bartonella (Rochalimaea) henselae or B. quintana causing bacillary angiomatosis and peliosis hepatitis.

    Syphilis with rapid (< 4 yr) appearance of neurosyphilis manifest by strokes, meningitis, and cranial nerve palsies and that is only transiently suppressed by penicillin regimens.


  • Tumors including the following (Jama 2001;285:1736): Kaposi sarcoma—HHV-8 coinfection, venerally spread among gay males



    • Sx/Si: Violaceous skin eruptions, ulcers on legs.


    • Crs: 80% mortality.


    • Diff Dx: bacillary angiomatosis.


    • Emergency Management: ID or HIV specialist referral, to consider intralesional HCG, interferon, vinblastine.

    Non-Hodgkins lymphoma, in 15% after 3 yr of AZT treatment.

    Burkitt’s lymphoma, EBV-associated, in adults.

    Leiomyosarcomas, EBV-associated, in children.

    Cervical cancer due to higher prevalence of HPV infection— Pap q 6 mon.


  • Gastrointestinal: upper gi hemorrhage, protease inhibitors helpful (Am J Gastroenterol 1999;94:358).


  • Hematologic: ITP and aplastic anemia—both of these from parvovirus infection and diminished half-life and megakaryocyte infection.


  • Metabolic: insulin resistance with protease inhibitor therapy (J Biol Chem 2000) and elevated lipid levels (AIDS Read; 2000;10:162,171).


  • Myocardiopathy


  • Neurologic includes the following:

    CNS degeneration leading to dementia.


    Progressive multifocal leukoencephalopathy (J Neurol 2000;247:134) associated with papovavirus, seen in transplant pts, as well.

    Cord lesions

    Meningitis (Arch IM 1995;155:2231), lower risk with fluconazole use.

    Peripheral neuropathy

    Cerebral toxoplasmosis

    Cerebral lymphomas


  • Nephropathy.


  • Rhematologic including Reiter’s without conjunctivitis, and psoriasis with arthritis.


  • Psychiatric includes depression and suicide.


  • Treatment may confer hyperglycemia and/or hyperlipidemia, but this does not limit treatment usefulness with concerns of increased vascular disease (CVA/ACS) in a preliminary study (Nejm 2003;348:702)




  • HTLV I infection, associated with paraparesis.


  • HTLV II infection, no disease association.


  • CD4 cell lymphopenia syndrome—rare and idiopathic disease.

Lab: Immunology:



  • Viral load, most important test; RNA by PCR, peripheral mononuclear cell viral m-RNA levels predict prognosis and treatment success; indicates rapidity of disease progression; < 10,000/cc, good; 10,000-100,000/cc, moderately OK; > 100,000/cc, bad. Consider genotyping/resistance testing of strain to guide therapy.


  • T4 (CD4) < 200/cc defines AIDS now and predicts opportunistic pneumonias; 200-500 = intermediate risk; a form of mile marker in disease progression.


  • ELISA with Western blot test, only 1.5% false pos in low-risk military population; if indeterminant, repeat in 1 mon and
    should become pos if really HIV; if persistently equivocal, get PCR and viral culture. Tests neg for 4+ mon incubation period. Peds with more variables (Ped Clin N Am 2000;47:39), peds referral.


  • Ora-Sure HIV-1 test from 2-min swab between cheek and gum as specific as serum by ELISA/Western blot.


  • p24 nuclear antigen detection either of free antigen or dissociated form IgG antibody-antigen complexes pos usually in early disease or in primary infection when ELISA still neg in 50%.

Routine: If newly diagnosed, CBC with diff, metabolic profile, hep B status, syphilis serology, baseline toxoplasmosis and CMV titers, PPD plus controls, UA warranted in that 10% have nephrotic syndrome. If known to be HIV positive, check other tests as warranted if evaluating secondary complaints. CXR if hypoxic or TB contacts (J Epidem Community Hlth 2000;54:64).

Emergency Management:

Immediate Public Health, Social Service (Am J Publ Hlth 2000;90:699) and Medical AIDS specialist referral, if AIDS-defining diagnosis is present.

If new diagnosis, consider the following:



  • Prevention: Condom use, AZT possibly with nevirapine (Nejm 2004;351:217) if pregnant—pre and post partum use decreases infant HIV positivity by one third. Protease inhibitors may predispose to low birth weight infants (Inf Dis Ob/Gyn 2000;8:94); this is a dynamic field


  • Haemophilus influenzae vaccine, Pneumovax, flu shot.


  • VZIG, if exposed to chickenpox.


  • Fluconazole 200 mg po q wk, if local mucosal or systemic candidal infections.

N.B. Treatment of disease a dynamic field (thus the guidelines are routinely updated) and saves lives (Lancet 2000;355:1131)—review
article of HIV counseling, testing and referral (Am Fam Phys 2004;70:295). Most would treat with CD4 < 200 or if symptomatic. If CD4 is > 350 and viral load < 55 most would monitor. Thus, significant “grey area” zone. Consultative resources for treating can be reached via the “Warm Line” 8 am to 8 pm Pacific Standard Time at 1-800-933-3413 (at University of California, San Francisco). Post-exposure prophylaxis guidance for HIV concerns can be reached at 1-800-448-4911.

Classes of drugs that may be considered are the following:



  • Nucleoside reverse transcriptase inhibitors: Zidovudine (AZT, ZDV; Retrovir), didanosine (ddI; Videx, Videx EC), zalcitabine (ddC; Hivid), stavudine (d4T; Zerit, Serit XR), lamivudine (3TC; Epivir), AZT/3TC (Combivir), abacavir (1592, ABC; Ziagen), AZT/3TC/ABC (Trizivir), emtricitabine (FTC; Emtriva)


  • Nucleotide reverse transcriptase inhibitor: tenofovir (TFV, TDF, PMPA; Viread).


  • Non-nucleoside reverse transcriptase inhibitors: nevirapine (NVP; Viramune), delavirdine (DLV; Rescriptor), efavirenz (EFV; Sustiva).


  • Protease inhibitors: HGC-saquinavir (SQV; Invirase), SGCsaquinavir (SQV; Fortovase), indinavir (IDV; Crixivan), ritonavir (RTV; Norvir), nelfinavir (NFV; Viracept), amprenavir (APV; Agenerase), lopinavir/ritonavir (ABT-378, LPV/r; Kaletra), atazanavir (ATV, Reyataz), fosamprenavir (f-APV; Lexiva).


  • Fusion inhibitor: enfuvirtide (T-20; Fuzeon).

Listing of available medications in The Medical Letter: Drugs for HIV Infection (Med Lett Drugs Ther 2001;43:103).

N.B. Avoid combinations of d4T + AZT; or ddC with ddI, d4t, or 3TC. Failure of treatment usually due to compliance and therapy potency (Jama 2000;283:205).


Specific Preventions:



  • Multivitamins delay disease progression (Nejm 2004;351:23).


  • Pneumocystis prophylaxis with CD4 counts 100-200 all 3 equally good so once a month pentamidine best since least toxic, but with CD4 counts < 100, TMP/SMX better than dapsone, which is better than pentamidine.


  • TB prevention for those tuberculin pos with either 1 yr of isoniazid or 2 mon of rifampin/pyrazinamide (Jama 2000;283:1445).


  • M. avium (MAI) prophylaxis if CD4 counts < 100 with clarithromycin, azithromycin, or rifabutin.


  • Toxoplasmosis after encephalitis with sulfadiazine and pyrimethoamine folate po qd or 3 times per week (Eur J Clin Microbiol Infect Dis 2000;19:89); or if pos titer and CD4 < 100 with TMP/SMX DS qd.


  • CMV infections with ganciclovir 1 gm po tid if CD4 < 50-100 decreases rate by half.


  • Cryptococcal with fluconazole, but no prolongation of survival.


  • Aphthous stomatitis with equal parts elixir of Mylanta: Benadryl: Tetracycline: Nystatin with 1 tsp qid swish and spit. Persistent cases—thalidomide 50-200 mg po qd × 2-4 wk (Clin Infect Dis 1995;20:250); or topical granulocytemacrophage colony-stimulating factor (Br J Dermatol 2000;142:171).


  • Wasting syndromes may be treated with megestrol (Megace) 40 mg po qid, or marijuana, androgens growth hormones or thalidomide.


  • Diarrhea should be treated by finding the primary cause with consideration of the following: octreotide 50 mg sc q 8 hr, opiates, loperamide (Imodium), or diphenoxylate-atropine (Lomotil). Endoscopy for refractory cases with negative stool studies (Gastrointest Endosc 2000;51:427).



  • Those responding to highly active anti-retroviral therapies may be considered for discontinuation of secondary prophylaxis for opportunistic infections (AIDS 2000;14:383; Nejm 2001;344:472).


  • Influenza vaccination, may require repeat boosters or prophylaxis with antiviral therapy (Ann IM 1988;109:383).


10.3 Influenza


Cause: An orthomyxovirus; viral infection with types A, B, and C (rare); the surface glycoproteins include those that contain hemagglutinin (H) or neuraminidase (N); the differences in H and N convey the different strains of influenza.

Epidem: Worldwide infection that usually occurs in the winter; attack rates as low as 20% and as high as 50%; variable course in children, with immunocompetence and age as partially determining factors.

Pathophys: Respiratory droplets spread (Nejm 1978;298:587); 2-d incubation with viral shedding beginning 1 d before symptoms and lasting about 1 wk.

Sx: Rigors, fever, sweating, cough, nasal congestion, inability to cope with daily activities, confined to bed (J Am Board Fam Pract 2004;17:1).

Si: Fever, adenopathy, wheezing or rhonchi, muscle tenderness.

Crs: Fever is up to 4 d, recovery from myalgias and fatigue may take weeks.

Complc: review article (BMJ 1966;5481:217)—anosmia, COPD exacerbation, encephalitis, Guillian-Barre, myocarditis, pericarditis, parotitis (Nejm 1977;296:1391); Reye syndrome, pneumonitis, pneumonia [synergism between influenza virus and Streptococcus pneumoniae (J Infect Dis 2003;187:1000)].


Diff Dx: Rhinovirus, parainfluenza virus, adenovirus, respiratory syncytial virus, Mycoplasma pneumoniae (Am Rv Respir Dis 1963;88:73); this upper respiratory syndrome may be also seen in those who inhale metals or polymers (Jama 1965;191:375).

Lab: (Med Lett Drugs Ther 1999;41:121) Consider point of care testing, such as Directigen Flu A Test with a 70% sensitivity and 92% specificity (J Clin Microbiol 2000;38:1161); Directigen Flu A + B test with sensitivities of 96% for type A, 88% for type B, and specificities of 99% for type A, 97% for type B (J Clin Microbiol 2002;74:1675); or ZstatFlu with a 65-77% sensitivity and 77-98% specificity (J Med Virol 2004;74:127). Review article for rapid testing—(Curr Opin Peds 2003;15:77). Confirmatory tests if needed may be agglutination-inhibition test (uncommon now) (Public Hlth Rep 1951;66:1195) culture, direct immunofluorescence, and/or PCR. Once influenza is known to be in your community for the season, empiric treatment for outpts based on symptoms is OK (Ann IM 2003;139:321). May want to test those in whom the therapy may be considered somewhat difficult, or if the patient is to be an inpatient.

Emergency Management:



10.4 Lyme Disease


Cause: Borrelia burgdorferi spread by Ixodes dammini tick bite—same tick also spreads babesiosis.


Epidem: Deer tick also infests white-footed deer mice. Northeastern and northwestern U.S. HLA DR4 and DRw2 B-cell allotypes associated with increased CNS, cardiac, and arthritic involvement. Most common tickborne spirochetal disease in U.S.; attack rates up to 66% of people living in a highly endemic area over 7 yr; annual incidence = 20-100 (or more) :100,000 per yr, depending on geographic locale (Jama 1997;278:112); also common in Northern Europe.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in EMERGENCY MEDICINE | Comments Off on Infectious Disease

Full access? Get Clinical Tree

Get Clinical Tree app for offline access